Month: March 2025
-
Trademark Showdown: Bullshine Distillery v. Sazerac Brands and the FIREBALL Controversy
On March 12, 2025, the Federal Circuit handed down its decision in Bullshine Distillery LLC v. Sazerac Brands, LLC, a case that highlights fundamental principles in trademark law, particularly the concepts of genericness and likelihood of confusion under the Lanham Act. The court affirmed the Trademark Trial and Appeal Board’s (TTAB) ruling that Sazerac’s FIREBALL…
-
Sierra Wireless v. Sisvel: (Dis)Qualification of Expert Witnesses in the PTAB
In its March 10, 2025 decision in Sierra Wireless, ULC v. Sisvel S.p.A., the Federal Circuit vacated a Patent Trial and Appeal Board (PTAB) decision due, in part, to the improper reliance on an expert witness who was not shown to possess the qualifications of a person of ordinary skill in the art (POSITA). For…
-
Federal Circuit Vacates PTAB Decision in CQV Co. v. Merck Patent GmbH, Raising Key Issues in Patent Infringement and Prior Art Analysis
The United States Court of Appeals for the Federal Circuit recently issued an opinion in CQV Co., Ltd. v. Merck Patent GmbH, vacating and remanding the Patent Trial and Appeal Board (PTAB) decision regarding U.S. Patent No. 10,647,861. The ruling focuses on key legal issues related to patent infringement, prior art determination, and procedural fairness…
-
Federal Circuit Revives Patent Infringement Case Over Quick-Release Tactical Vest System
In a recent decision, the United States Court of Appeals for the Federal Circuit vacated a district court’s summary judgment ruling of noninfringement in IQRIS Technologies LLC v. Point Blank Enterprises, Inc., and National Molding, Inc. The ruling focuses on a dispute over the proper interpretation of the term “pull cord” in IQRIS Technologies’ patents…
-
Patent Battles in Wearable Tech: AliveCor v. Apple and the Fight Over Arrhythmia Detection
On March 7, 2025, the Federal Circuit issued its decision in AliveCor, Inc. v. Apple Inc., upholding the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) ruling that invalidated AliveCor’s patents on heart rate monitoring technology. The case has significant implications for the wearable technology industry, particularly in the areas of patentability,…
-
Patent Law and Drug Innovation: Federal Circuit Upholds Rejection of ImmunoGen’s Patent Application
On March 6, 2025, the Federal Circuit issued its opinion in ImmunoGen, Inc. v. Stewart, affirming the district court’s ruling that denied ImmunoGen’s patent application for a dosing regimen of its antibody drug conjugate (ADC), IMGN853. The court’s decision, rooted in key principles of intellectual property law, particularly focused on the doctrines of indefiniteness and…
-
Navigating Patent Law After Arthrex: The Federal Circuit’s Decision in Odyssey Logistics v. Stewart
The Federal Circuit’s recent decision in Odyssey Logistics & Technology Corp. v. Stewart (No. 23-2077) highlights the ongoing implications of the Supreme Court’s Arthrex decision on the United States Patent and Trademark Office (USPTO) and its review processes. This case revolves around a long-disputed patent application, constitutional challenges under the Appointments Clause, and the procedural…
-
Navigating Antidumping Duties and International Trade: A Review of Vandewater v. United States
On March 6, 2025, the United States Court of Appeals for the Federal Circuit issued a decision in Vandewater International Inc. v. United States, affirming the Department of Commerce’s determination that certain steel branch outlets imported by Vandewater fell within the scope of an existing antidumping duty (ADD) order. This ruling underscores the complex interplay…
-
Court of Appeals Decision in Lashify, Inc. v. International Trade Commission: Key Takeaways
On March 5, 2025, the United States Court of Appeals for the Federal Circuit issued a decision in Lashify, Inc. v. International Trade Commission, a case concerning intellectual property rights in the context of international trade and the domestic industry requirement under Section 337 of the Tariff Act of 1930. The ruling has significant implications…
-
Federal Circuit Upholds Patentability of Stem Cell Technology in Restem v. Jadi Cell
The United States Court of Appeals for the Federal Circuit recently issued a significant ruling in Restem, LLC v. Jadi Cell, LLC, upholding the validity of Jadi Cell’s U.S. Patent No. 9,803,176. This case, which originated from an inter partes review (IPR) before the Patent Trial and Appeal Board (PTAB), revolved around whether Restem could…